FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013299670> ?p ?o ?g. }

• W3013299670 abstract "Introduction: Germline pathogenic variants in genes in the homologous recombination (HR) pathway such as BRCA1, BRCA2, ATM, PALB2, RAD51C and RAD51D confer an increased risk of breast and ovarian cancers. Screening for germline variants in these cancer susceptibility genes is critical as prophylactic measures and monitoring can be performed in these individuals to minimize their risk of developing breast and/or ovarian cancers. More recently, it has been recognized that cancers arising in carriers of germline pathogenic (P)/ likely pathogenic (LP) variants in HR genes often show a homologous recombination (HR) deficient (HRD) phenotype and can be targeted with platinum agents or PARP inhibitors. RAD51B is a RAD51 paralog that binds to RAD51C and functions as a heterodimer in the HR pathway. Whilst RAD51B germline variants have been reported in isolated cases of breast and ovarian cancers, it is unclear as to whether RAD51B P/LP germline variants would confer predisposition to these cancer types. Materials and Methods: We screened 9,287 consecutive unselected cancer patients who consented for both tumor and germline testing using the MSK-IMPACT platform for the presence of RAD51B germline truncating variants. Selected RAD51B germline mutant breast cancers identified by MSK-IMPACT were subjected to whole-exome sequencing (WES) analysis to determine the dominant mutational signatures using DeconstructSigs. Functional assays were performed to ascertain the impact of RAD51B loss on HR DNA repair and PARP inhibitor sensitivity using genome editing methods in non-malignant breast epithelial cell lines. Results: Out of the 9,287 cancer patients, we detected likely pathogenic loss of function RAD51B germline variants in 11 patients (0.12%), which was similar to the frequency detected in the gnomAD database (0.09%). All female carriers of RAD51B loss of function variants (n=8) had breast or ovarian cancers (8/1,619 breast or ovarian cancers, 0.5%). The observed carrier frequencies of germline truncating variants in RAD51B was statistically enriched in breast and ovarian cancer patients compared to individuals in the gnomAD database (0.5% vs 0.09% P=0.0003; odds ratio = 5.06 (95% CI: 2.1-10.3)). Although segregation studies were not available, 9/11 of the RAD51B germline loss of function variant carriers had a personal or family history of breast or ovarian cancers. All five breast and ovarian cancers from RAD51B mutation carriers investigated by WES were found to harbor RAD51B bi-allelic inactivation through loss of heterozygosity of the RAD51B wild-type allele. In addition, these five cases were found to display genomic features of HRD including high large-scale state transition scores and a dominant mutational signature 3. CRISPR/Cas9 genome editing of RAD51B in a non-malignant breast epithelial cell model revealed that RAD51B deficient cells display PARP inhibitor sensitivity similar to that reported in BRCA1 and BRCA2 deficient cell lines. Conclusion: RAD51B loss-of-function germline variants confer susceptibility to breast and ovarian cancer development. Breast and ovarian cancers occurring in the context of RAD51B germline mutations harbor bi-allelic inactivation of RAD51B through loss-of-heterozygosity of the wild-type allele, genomic features of HRD and are likely sensitive to PARP inhibition. Albeit rarely germline mutated, RAD51B should be considered as an addition to clinical germline testing panels for hereditary breast and ovarian cancer syndrome patients. Citation Format: Diana SReis-FilhoReis-Filho Mandelker, Semanti Mukherjee, Jeremy Setton, Pier Selenica, Yelena Kemel, Ozge Ceyhan-Birsoy, Margaret Sheehan, Kaitlyn Tkachuk, David N Brown, Simon Powell, Britta Weigelt, Mark E Robson, Nadeem Riaz, Kenneth Offit, Jorge S Reis-Filho. RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-09-01." @default.
• W3013299670 created "2020-04-03" @default.
• W3013299670 creator A5001757617 @default.
• W3013299670 creator A5010862515 @default.
• W3013299670 creator A5014140313 @default.
• W3013299670 creator A5027048828 @default.
• W3013299670 creator A5039769423 @default.
• W3013299670 creator A5040506127 @default.
• W3013299670 creator A5045514288 @default.
• W3013299670 creator A5047642576 @default.
• W3013299670 creator A5056895130 @default.
• W3013299670 creator A5065535144 @default.
• W3013299670 creator A5069046147 @default.
• W3013299670 creator A5076824413 @default.
• W3013299670 creator A5077235697 @default.
• W3013299670 creator A5078720067 @default.
• W3013299670 creator A5081041480 @default.
• W3013299670 date "2020-02-14" @default.
• W3013299670 modified "2023-09-27" @default.
• W3013299670 title "Abstract P6-09-01: RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects" @default.
• W3013299670 doi "https://doi.org/10.1158/1538-7445.sabcs19-p6-09-01" @default.
• W3013299670 hasPublicationYear "2020" @default.
• W3013299670 type Work @default.
• W3013299670 sameAs 3013299670 @default.
• W3013299670 citedByCount "0" @default.
• W3013299670 crossrefType "proceedings-article" @default.
• W3013299670 hasAuthorship W3013299670A5001757617 @default.
• W3013299670 hasAuthorship W3013299670A5010862515 @default.
• W3013299670 hasAuthorship W3013299670A5014140313 @default.
• W3013299670 hasAuthorship W3013299670A5027048828 @default.
• W3013299670 hasAuthorship W3013299670A5039769423 @default.
• W3013299670 hasAuthorship W3013299670A5040506127 @default.
• W3013299670 hasAuthorship W3013299670A5045514288 @default.
• W3013299670 hasAuthorship W3013299670A5047642576 @default.
• W3013299670 hasAuthorship W3013299670A5056895130 @default.
• W3013299670 hasAuthorship W3013299670A5065535144 @default.
• W3013299670 hasAuthorship W3013299670A5069046147 @default.
• W3013299670 hasAuthorship W3013299670A5076824413 @default.
• W3013299670 hasAuthorship W3013299670A5077235697 @default.
• W3013299670 hasAuthorship W3013299670A5078720067 @default.
• W3013299670 hasAuthorship W3013299670A5081041480 @default.
• W3013299670 hasConcept C102744134 @default.
• W3013299670 hasConcept C104317684 @default.
• W3013299670 hasConcept C109825262 @default.
• W3013299670 hasConcept C121608353 @default.
• W3013299670 hasConcept C134935766 @default.
• W3013299670 hasConcept C13514818 @default.
• W3013299670 hasConcept C2776071976 @default.
• W3013299670 hasConcept C2778144015 @default.
• W3013299670 hasConcept C2778502085 @default.
• W3013299670 hasConcept C2779012473 @default.
• W3013299670 hasConcept C2780427987 @default.
• W3013299670 hasConcept C2909462720 @default.
• W3013299670 hasConcept C501734568 @default.
• W3013299670 hasConcept C502942594 @default.
• W3013299670 hasConcept C530470458 @default.
• W3013299670 hasConcept C54355233 @default.
• W3013299670 hasConcept C86803240 @default.
• W3013299670 hasConceptScore W3013299670C102744134 @default.
• W3013299670 hasConceptScore W3013299670C104317684 @default.
• W3013299670 hasConceptScore W3013299670C109825262 @default.
• W3013299670 hasConceptScore W3013299670C121608353 @default.
• W3013299670 hasConceptScore W3013299670C134935766 @default.
• W3013299670 hasConceptScore W3013299670C13514818 @default.
• W3013299670 hasConceptScore W3013299670C2776071976 @default.
• W3013299670 hasConceptScore W3013299670C2778144015 @default.
• W3013299670 hasConceptScore W3013299670C2778502085 @default.
• W3013299670 hasConceptScore W3013299670C2779012473 @default.
• W3013299670 hasConceptScore W3013299670C2780427987 @default.
• W3013299670 hasConceptScore W3013299670C2909462720 @default.
• W3013299670 hasConceptScore W3013299670C501734568 @default.
• W3013299670 hasConceptScore W3013299670C502942594 @default.
• W3013299670 hasConceptScore W3013299670C530470458 @default.
• W3013299670 hasConceptScore W3013299670C54355233 @default.
• W3013299670 hasConceptScore W3013299670C86803240 @default.
• W3013299670 hasLocation W30132996701 @default.
• W3013299670 hasOpenAccess W3013299670 @default.
• W3013299670 hasPrimaryLocation W30132996701 @default.
• W3013299670 hasRelatedWork W12002835 @default.
• W3013299670 hasRelatedWork W13936927 @default.
• W3013299670 hasRelatedWork W14498073 @default.
• W3013299670 hasRelatedWork W1452304 @default.
• W3013299670 hasRelatedWork W15026497 @default.
• W3013299670 hasRelatedWork W161059 @default.
• W3013299670 hasRelatedWork W2140235 @default.
• W3013299670 hasRelatedWork W3549485 @default.
• W3013299670 hasRelatedWork W4094339 @default.
• W3013299670 hasRelatedWork W8041353 @default.
• W3013299670 isParatext "false" @default.
• W3013299670 isRetracted "false" @default.
• W3013299670 magId "3013299670" @default.
• W3013299670 workType "article" @default.